Jasleen Randhawa, MD

  • Houston Methodist hematology and hematologic malignancy oncologist
  • Assistant Professor of Clinical Medicine in Oncology, Houston Methodist Institute for Academic Medicine 
  • Assistant Professor of Clinical Medicine, Weill Cornell Medical College

Jasleen Randhawa, MD

Areas of Expertise

  • Acute lymphocytic leukemia
  • Acute myelogenous leukemia
  • Anemia
  • Bone marrow aspiration and biopsy
  • Cancer clinical trials
  • Chronic lymphocytic leukemia
  • Chronic myelogenous leukemia
  • General hematology
  • Hematology oncology
  • Multiple myeloma
  • Myelodysplastic neoplasms
  • Myelodysplastic syndrome
  • Myelodysplastic syndrome
  • Non-Hodgkin and Hodgkin lymphoma
  • T-Cell lymphoma

Credentials

MEDICAL SCHOOL
Dayanand Medical College-Ludhiana, India | 2007
RESIDENCY
Medical College of Wisconsin - Internal Medicine - Milwaukee | 2010
FELLOWSHIP
Medical College of Wisconsin - Hematology Oncology - Milwaukee | 2014
MD Anderson Cancer Center - Leukemia - Houston | 2015
BOARD CERTIFICATION
Internal Medicine, Hematology, Oncology

Publications

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
Dalle, IA, Cortes, JE, Pinnamaneni, P, Lamothe, B, Duque, AD, Randhawa, J, Pemmaraju, N, Jabbour, E, Ferrajoli, A, Wierda, WG, Estrov, Z, Konopleva, M, Ravandi, F, Alvarado, Y, Borthakur, G, Gandhi, V & Kantarjian, HM 2018, Acta Haematologica, vol. 140, no. 1, pp. 30-39. https://doi.org/10.1159/000490092

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival
Hari, P, Reece, DE, Randhawa, J, Flomenberg, N, Howard, DS, Badros, AZ, Rapoport, AP, Meisenberg, BR, Filicko-Ohara, J, Phillips, GL & Vesole, DH 2018, , Bone Marrow Transplantation, pp. 1-7. https://doi.org/10.1038/s41409-018-0261-y

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
Daher, M, Hidalgo Lopez, JE, Randhawa, JK, Jabbar, KJ, Wei, Y, Pemmaraju, N, Borthakur, G, Kadia, T, Konopleva, M, Kantarjian, HM, Hearn, K, Estrov, Z, Reyes, S, Bueso-Ramos, CE & Garcia-Manero, G 2017, , American Journal of Hematology, vol. 92, no. 7, pp. 674-682. https://doi.org/10.1002/ajh.24746


Allogeneic hematopoietic cell transplantation in multiple myeloma
Randhawa, J, Singh, V & Hari, P 2014, . in Cancer Consult: Expertise for Clinical Practice. Wiley, pp. 381-387. https://doi.org/10.1002/9781118589199.ch60


Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
Randhawa, J, Ostojic, A, Vrhovac, R, Atallah, E & Verstovsek, S 2012, , Journal of Hematology and Oncology, vol. 5, 43. https://doi.org/10.1186/1756-8722-5-43

Languages

  • English